KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Debt (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Total Debt data on record, last reported at $37.5 million in Q4 2025.

  • For Q4 2025, Total Debt rose 15.33% year-over-year to $37.5 million; the TTM value through Dec 2025 reached $37.5 million, up 15.33%, while the annual FY2025 figure was $37.5 million, 15.33% up from the prior year.
  • Total Debt reached $37.5 million in Q4 2025 per AQST's latest filing, up from $36.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $54.2 million in Q1 2022 and bottomed at $16.1 million in Q1 2024.
  • Average Total Debt over 5 years is $38.6 million, with a median of $38.6 million recorded in 2021.
  • Peak YoY movement for Total Debt: crashed 61.92% in 2024, then soared 109.22% in 2025.
  • A 5-year view of Total Debt shows it stood at $53.6 million in 2021, then fell by 2.67% to $52.1 million in 2022, then crashed by 47.21% to $27.5 million in 2023, then rose by 18.15% to $32.5 million in 2024, then increased by 15.33% to $37.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $37.5 million in Q4 2025, $36.3 million in Q3 2025, and $35.0 million in Q2 2025.